Neoadjuvant endocrine therapy versus chemotherapy in patients with hormone dependent (ER+) breast cancer

V. F. Semiglazov; Семиглазов В. Ф.; V. V. Semiglazov; Семиглазов В. В.; G. A. Dashyan; Дашян Г. А.; E. K. Zhiltsova; Жильцова Е. К.; V. G. Ivanov; Иванов В. Г.; A. A. Bozhok; Божок А. А.; R. M. Paltuev; Палтуев Р. М.; O. A. Melnikova; Мельникова О. А.; A. A. Kletcel; Клетцель А. А.; R. V. Donskikh; Донских Р. В.; I. A. Kochetova; Кочетова И. А.; A. O. Damenia; Дамениа А. О.; K. Y. Zernov; Зернов К. Ю.; D. A. Voskresenskey; Воскресенский Д. А.; L. M. Bershteyn; Берштейн Л. М.

Neoadjuvant endocrine therapy versus chemotherapy in patients with hormone dependent (ER+) breast cancer

Authors: Semiglazov V.F.¹, Semiglazov V.V.¹, Dashyan G.A.¹, Zhiltsova E.K.¹, Ivanov V.G.¹, Bozhok A.A.¹, Paltuev R.M.¹, Melnikova O.A.¹, Kletcel A.A.¹, Donskikh R.V.¹, Kochetova I.A.¹, Damenia A.O.¹, Zernov K.Y.¹, Voskresenskey D.A.¹, Bershteyn L.M.¹
Affiliations:
1. N. N. Petrov Institute of Oncology
Issue: Vol 7, No 3 (2007)
Pages: 59-69
Section: Clinical medicine
Published: 07.08.2007
URL: https://journals.eco-vector.com/MAJ/article/view/694211
ID: 694211

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

This randomized controlled phase II study evaluated the efficacy of neoadjuvant chemotherapy (doxorubicin + paclitaxel) compared with endocrine treatment with aromatase inhibitors (anastrazole or exemestane) in postmenopausal women with ER-positive and/or PgR-positive breast cancer. Preoperative neoadjuvant endocrine therapy with aromatase inhibitors was well tolerated and resulted in similar rates of overall objective response and breast-conserving surgery as chemotherapy in postmenopausal women with ER-positive and/or PgR-positive tumors.

Keywords

neoadjuvant aromatase, inhibitors, primary chemotherapy, breast neoplasms

About the authors

V. F. Semiglazov

N. N. Petrov Institute of Oncology

Author for correspondence.
Email: shabanov@mail.rcom.ru

член-корреспондент РАМН

Russian Federation, St. Petersburg

References

Семиглазов В. Ф., Семиглазов В. В., Клецелъ А. Е. Неинвазивные и инвазивные опухоли молочной железы. М.: «Боргесе», 2006. 349 с.
Abrial С., Mouret-Reynier М. A., Cure Н. et al. Neoadjuvant endocrine therapy in breast cancer // Breast. 2006. Vol. 15. P. 9-19.
Bear H. D., Anderson S., Smith R. E. et al. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 // J. Clin. Oncol. 2006. Vol. 24. P. 2019-2027.
Bhatnagar A., Batzl C., Hausler A. et al. Pharmacology of non-steroidal aromatase inhibitors / Pasqualini J., Katzenellenbogen B., eds // Hormone-Dependent Cancer (New York: Marcel Dekker). 1996. P. 155-168.
Bonadonna G., Valagussa P, Brambilla C. et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute // J. Clin. Oncol. 1998. Vol. 16. P 93-100.
Bonadonna G. From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture-1992 // Int. J. Cancer. 1993. Vol. 55. P. 1-4.
Cameron D. A., Anderson E. D., Levack P. et al. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy // Br. J. Cancer. 1997. Vol. 76. P. 1099-1105.
Castiglione-Gertsh M. Adjuvant endocrine therapies for postmenopausal women: standards and not [Abstract S24] // Breast. 2005. Vol. 14 (suppl. 1). S9.
Colleoni M., Gelber S., Coates A. S. et al. Influ¬ence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer // J. Clin. Oncol. 2001. Vol. 19. P. 4141-4149.
Common Terminology Criteria for Adverse Events v3. 0 (CTCAE) // National Cancer Institute. 2006. Available from: http: // ctep. cancer. gov/reporting/ctc_v30. html. accessed January 16, 2007.
Coombes R. C., Hall E., Gibson L. J. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer // N. Engl. J. Med. Mar. 2004. Vol. 350. P. 1081-1092.
Davidson N.E., Morrow М. Sometimes a great notion - An assessment of neoadjuvant systemic therapy for breast cancer // J. Natl. Cancer. Inst. 2005. Vol. 97. P. 159-161.
Dixon J., Anderson T., Miller W. Phase lib study of neoadjuvant exemestane (EXE) in locally advanced breast cancer // Proc. Am. Soc. Clin. Oncol. 2001. Vol. 20. Abstract 1908.
Dixon J. M., Bundred N. Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies // Eur. J. Surg. Oncol. 2006. Vol. 32. P. 123-125.
Eiermann W, Paepke S., Appfelstaedt J. et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study // Ann. Oncol. 2001. Vol. 12. P. 1527-1532.
Ellis M. J., Coop A., Singh B. et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial // J. Clin. Oncol. 2001. Vol. 19. P. 3 808-3 816.
Fisher B., Bryant J., Wolmark N. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer // J. Clin. Oncol. 1998. Vol. 16. P. 2672-2685.
Fleiss J. L. The Design and Analysis of Clinical Experiments. New York: John Wiley and Sons, 1986.
Gazet J. C, Ford H. T., Coombes R. C. et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer // Eur. J. Surg. Oncol. 1994. Vol. 20. P. 207-214.
Gianni L., Baselga J., Eiermann W. et al. Feasi¬bility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy // Clin. Cancer. Res. 2005. Vol. 11. P. 8715-8721.
Gianni L., Baselga J., Eiermann W. et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease // Proc. Am. Soc. Clin. Oncol. 2002. Vol. 21. Abstract 132.
Gil M., Barnadas A., Cirera L. et al. Exemestane as neoadjuvant treatment in patients >65 years with T>3cm; preliminary results of a multicenter Spanish phase II trial [Abstract] // Paper presented at: San Antonio Breast Cancer Symposium. 2002 (San Antonio, TX).
Kaufmann M., Hortobagyi G. N., Goldhirsch A. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update // J. Clin. Oncol. 2006. Vol. 24. P. 1940-1949.
Kaufmann M., von Minckwitz G., Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer// Breast. 2005. Vol. 14. P. 576-581.
Krainick U., Astner A., Jonat W., Wallwiener D. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancerfinal results of the German Neoadjuvant Aromasin Initiative (GENARI) [Abstract] // Breast Cancer. Res. Treat. 2003. Vol. 82. P. 55.
Lichtenegger W, Hackl W, Huettner C. et al. Exemestane combined with weekly docetaxel as preoperative treatment for breast cancer [Abstract] // Proc. Am. Soc. Clin. Oncol. 2001. Vol. 20. Abstract 1832.
Makris A., Powles T. J., Ashley S. E. et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer // Ann. Oncol. Nov. 1998. Vol. 9. P. 1179-1184.
Mauri D., Pavlidis N., loannidis J. P Neoadjuvant versus adjuvant systemic treatment for breast cancer: a meta-analysis // J. Natl. Cancer. Inst. 2005. Vol. 97. P. 188-194.
Mauriac L., Debled M., Durand M. et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women // Ann. Oncol. 2002. Vol. 13. P. 293-298.
Robertson J. F, Ellis I. O., Elston C. W, Blarney R. W. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up // Eur. J. Cancer. 1992. Vol. 28A. P. 908-910.
Scholl S. M., Fourquet A., Asselain B. et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial // Eur. J. Cancer. 1994. Vol. 30A. P. 645-652.
Schwartz G. E, Birchansky C. A., Komarnicky L. T. et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast // Cancer. 1994. Vol. 73. P. 362-369.
Semiglazov V., Ivanov V., Ziltzova E. et al. Neoadjuvant endocrine therapy of postraenopausal breast cancer patients // Proceeding of Fourteenth International Congress on Anti-cancer Treatment. 2003. Paris. P. 174.
Semiglazov K, Kletsel A., Semiglazov V. et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0) [Abstract] // J. Clin. Oncol. 2005. Vol. 23. P. 530.
Semiglazov V. F, Semiglazov V. V., Ivanov И et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in post-menopausal women with ER-positive breast cancer // J. Clin. Oncol. 2004. Vol. 22. P. 519.
Semiglazov V. E, Topuzov E. E., Bavli J. L. et al. Primary (neoadjuvant) chemotherapy and radio-therapy compared with primary radiotherapy alone in stage Ilb-IIIa breast cancer // Ann. Oncol. 1994. Vol. 5. P. 591-595.
Smith I. C., Heys S. D., Hutcheon A. W et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel // J. Clin. Oncol. 2002. Vol. 20. P. 1456-1466.
Tubiana-Hulin M., Spyratos F, Вecette V. et al. Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer [Abstract] // Breast Cancer Res. Treat. 2003. Vol. 82. P. 106.
Winer E. P, Hudis C., Burstein H. J. et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004 // J. Clin. Oncol. 2005. Vol. 23. P. 619-629.
Wolf C., Hackl W, Kuemper S., Scheme T., Eiermann W Exemestane combined with epirubicin, Qlw X (8-12), as preoperative chemoendocrine treatment for patients with primary breast cancer: a phase I study // Proc. Am. Soc. Clin. Oncol. 2001. Vol. 20. Abstract 1819.
Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-year Results From National Surgical Adjuvant Breast and Bowel Project B-18 // J. of the Nat. Cancer Institute Monogr. 2001. Vol. 3 0. P. 96-102.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register